Andrew Tsai

“Back to essential tremor, there really, to me at least, seems to be a chance maybe ET could be approved earlier than expected, especially if this mid-cycle review is done, inspections are done is it the right thinking that you will be entering final labeling discussions soon or if not can you just remind us what the…”

“Yeah, so on the 7.6.5 program, I was hoping maybe you guys could talk about your prior Phase 2 data and maybe what exactly gives you confidence that you could succeed in Phase 3 and maybe even why efficacy could look even better in Phase 3.”

“I have a question about the regulatory strategy for the SRNA programs because given you guys have the desire to start pivotal studies, can you maybe talk about your latest thinking and whether you plan to pursue accelerated approval or full approval for both indications and what do you envision your primary endpoint…”

“Thanks for joining me, and it's my pleasure to have Ryan Watts, CEO of Denali, joining me today. Welcome, Ryan.”

“We're going to get started with our next session. I'm Andrew Tsai, Senior Biotech Analyst at Jefferies. Thanks for joining me today. And it's my pleasure to have the Bridge Bio team with me.”